全球腫瘤體內研究 (CRO) 市場規模（按地區、範圍和預測）

腫瘤體內研究（CRO）的全球市場規模與預測

2024 年全球體內腫瘤學 (CRO) 市場規模價值為 20.7 億美元，預計到 2031 年將達到 36.1 億美元，2024 年至 2031 年的複合年增長率為 8.1%。腫瘤學體內研究和治療均在體內進行。它涉及直接研究活體動物（例如小鼠或人類）的癌症行為、進展和對藥物的反應，目的是比單純的試管方法更準確地設計和測試新的治療方法和乾預措施。

體內腫瘤學方法對於研究癌症進展和治療成功至關重要。活體動物模型用於評估腫瘤的發展、轉移和治療效果。這些技術將有助於開發標靶治療方法、評估藥物毒性、提高對癌症生物學的認識，所有這些都有助於推進個人化醫療並改善患者的治療效果。

腫瘤體內研究方法有望透過更精確的腫瘤追蹤、即時藥物反應監測和改進的診斷影像來徹底改變個人化癌症治療。這些技術將改善標靶治療，減少副作用並簡化早期檢測，從而實現更有效和個人化的癌症治療。

全球腫瘤體內研究 (CRO) 市場動態

影響全球癌症體內研究（CRO）市場的關鍵市場動態是：

主要市場驅動因子

癌症發生率上升：

癌症發生率不斷上升：國際上癌症發生率呈上升趨勢。這種激增促使對有效治療和診斷技術的需求日益增長。體內模型對於藥物研發和行銷至關重要，並正在推動市場成長。

生物技術的進步：

生物技術的創新使得藥物開發變得越來越複雜和客製化。體內模型對於評估這些創新療法至關重要，從而推動市場成長。

增加研發投入：

製藥和生技公司正在大力投資癌症研究。這些不斷增加的研發成本正在產生對體內模型的需求，以幫助藥物發現和開發。

監理機關核准與市場准入：

如果一種抗癌藥物成功通過臨床試驗並獲得監管部門的批准，它就可以進入市場。這些療法的商業化通常需要使用體內模型來獲得大量臨床前數據，從而推動市場需求。

主要問題

成本高：

由於模型生物的成本、專用設備和員工技能等因素，開發和進行體內腫瘤學研究的成本極為昂貴。這可能會給小型生物科技公司和學術機構帶來障礙。

模型限制：

雖然體內模型很有用，但它們無法完全重現人類腫瘤微環境和疾病進展。這會影響研究成果的轉化相關性和藥物開發的成功率。

道德考量：

在研究中使用動物會引發倫理問題。公眾監督、監管障礙以及嚴格的倫理審查流程的需求都會增加體內研究的時間和成本。

資料標準化與共享：

研究設計、數據報告和分析的不一致導致結果難以比較和重現。制定既定協議並促進數據共享對於加速藥物開發至關重要。

主要趨勢：

越來越關注免疫腫瘤學：

對於研究癌症免疫反應的體內模型的需求日益增加。這一趨勢是由免疫療法的日益成功以及創新免疫藥物的臨床前測試的需求所推動的。

個人化醫療：

個人化醫療正在推動對病患衍生模型的需求，強調產生有效代表人類腫瘤生物學的體內模型。患者來源異種移植 (PDX) 模型越來越受歡迎，因為它們能夠實現客製化的治療方案和藥物開發。

採用尖端技術：

人工智慧、機器學習和影像處理等現代技術的引入正在徹底改變體內研究。這些技術增強了數據處理能力，加快了藥物研發速度，並有助於預測臨床結果。

更重視法規遵循與資料完整性：

監管機構正在更詳細地分析臨床前數據。 CRO 和製藥公司正在投資強大的品質控制系統和資料完整性實踐，以確保合規性和研究結果的可信度。

目錄

第 1 章簡介

• 市場定義
• 市場區隔
• 研究方法

第 2 章執行摘要

• 主要發現 市場概況
• 市場亮點

第3章 市場概覽

• 市場規模與成長潛力
• 市場趨勢
• 市場推動因素
• 市場限制
• 市場機會
• 波特五力分析

第 4 章腫瘤體內研究 (CRO) 市場（按服務類型）

• 藥物動力學研究
• 毒性測試
• 效能研究
• 生物分析與分析服務

第 5 章腫瘤體內研究 (CRO) 市場（按適應症劃分）

• 實體腫瘤
• 血液系統惡性腫瘤
• 其他

第 6 章 腫瘤體內 (CRO) 市場（依最終用戶）

• 製藥和生技公司
• 合約研究組織 (CRO)
• 學術和研究機構
• 其他

第 7 章 區域分析

• 北美洲
• 美國
• 加拿大
• 墨西哥
• 歐洲
• 英國
• 德國
• 法國
• 義大利 亞太地區
• 中國
• 日本
• 印度
• 澳大利亞
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中東和非洲
• 南非
• 沙烏地阿拉伯
• 阿拉伯聯合大公國

第 8 章 市場動態

• 市場推動因素
• 市場限制
• 市場機會
• COVID-19 對市場的影響

第 9 章 競爭格局

• 大型公司
• 市佔率分析

第10章 公司簡介

• Charles River Laboratories International Inc.
• Envigo CRS
• Eurofins Scientific SE
• Icon plc
• Labcorp Co. Holdings
• Medpace Holdings Inc.
• PAREXEL International Corporation
• Pharmaceutical Product Development LLC（PPD）
• Syneos Health Inc.
• WuXi AppTec Co., Ltd.

第 11 章 市場展望與機會

• 新興技術
• 未來市場趨勢
• 投資機會

第 12 章附錄

• 縮寫列表
• 來源與參考文獻

Global Oncology Based In Vivo (CRO) Market Size and Forecast

Global Oncology Based In Vivo (CRO) Market size was valued at USD 2.07 Billion in 2024 and is projected to reach USD 3.61 Billion by 2031 growing at a CAGR of 8.1% from 2024 to 2031. Oncology-based in vivo research or treatment occurs within a living creature. It entails researching cancer's behavior, progression and response to medicines directly in living animals, such as mice or humans, in order to design and test new treatments and interventions more accurately than in vitro approaches alone.

Oncology-based in vivo approaches are critical for investigating cancer progression and therapy success. They use live animal models to assess tumor development, metastasis and therapy response. These technologies aid in the development of targeted therapies, the assessment of drug toxicity and the knowledge of cancer biology, all of which contribute to the advancement of personalized medicine and better patient outcomes.

Oncology-based in vivo approaches will revolutionize individualized cancer treatment by allowing for more precise tumor tracking, real-time medication response monitoring and improved imaging for diagnosis. These technologies will improve targeted therapy, reduce side effects and simplify early detection, resulting in more effective and personalized cancer treatment.

Global Oncology Based In Vivo (CRO) Market Dynamics

The key market dynamics that are shaping the global oncology based in vivo (CRO) market include:

Key Market Drivers:

Increasing Cancer Prevalence:

Cancer prevalence is rising internationally. This surge increases the demand for effective therapies and diagnostic technologies. In vivo models are critical for drug discovery and development, which drives market growth.

Advances in Biotechnology:

Biotechnology innovations are enabling the development of increasingly complicated and tailored medicines. In vivo models are critical for assessing these innovative treatments and driving market growth.

Increasing R&D Investment:

Pharmaceutical and biotechnology corporations are investing considerably in cancer research. This increasing R&D spending creates a demand for in vivo models to help drug discovery and development pipelines.

Regulatory Approval and Market Entry:

Successful clinical studies and subsequent regulatory approvals for oncology treatments result in market launch. Commercialization of these medications frequently requires substantial preclinical data acquired utilizing in vivo models, thereby enhancing market demand.

Key Challenges:

High Costs:

Developing and carrying out in vivo oncology studies is exceedingly expensive because to factors such as model organism costs, specialized equipment and staff skills. This may impede smaller biotech enterprises and academic organizations.

Model Limitations:

While in vivo models are useful, they cannot fully replicate human tumor microenvironments and disease progression. This can have an impact on the translational significance of study findings and drug development success rates.

Ethical Considerations:

Using animals in research creates ethical issues. Public attention, regulatory impediments and the requirement for robust ethical review processes can all add to the time and cost of in vivo research.

Data Standardization and Sharing:

Inconsistent study design, data reporting and analysis make it difficult to compare and reproduce results. Creating established protocols and encouraging data sharing crucial for accelerating drug development.

Key Trends:

Increasing Focus on Immuno-oncology:

The demand for in vivo models to investigate immune responses to cancer is increasing. This trend is being pushed by the increasing success of immunotherapy and the necessity for preclinical testing of innovative immune-based medicines.

Personalized Medicine:

Personalized medicine is driving the demand for patient-derived models there is a rising emphasis on creating in vivo models that effectively represent human tumor biology. Patient-derived xenograft (PDX) models are gaining popularity since they enable tailored treatment options and drug development.

Adoption of Advanced Technology:

The incorporation of modern technology such as AI, machine learning and imaging is revolutionizing in vivo research. These techniques increase data processing, speed up drug discovery and help anticipate clinical outcomes.

Increasing Emphasis on Regulatory Compliance and Data Integrity:

Regulatory authorities are analyzing preclinical data more closely. CROs and pharmaceutical companies are investing in robust quality management systems and data integrity practices to ensure compliance and trust in research findings.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Oncology Based In Vivo (CRO) Market Regional Analysis

Here is a more detailed regional analysis of the global oncology based in vivo (CRO) market:

North America:

According to Verified Market Research, North America is expected to dominate the global oncology based in vivo (CRO) market.

North America is predicted to dominate the global oncology-based in vivo Contract Research Organization (CRO) market, owing to its strong healthcare infrastructure, large investment in cancer research and concentration of top pharmaceutical and biotechnology businesses.

The region's advanced technology, skilled labor and regulatory support contribute to its market supremacy. Furthermore, North America's large clinical trial networks and early adoption of novel oncology treatments add to its dominance.

As the region continues to push advances in customized medicine and targeted therapeutics, it stays at the forefront of the oncology-based in vivo CRO market, influencing worldwide trends and standards.

Asia Pacific:

According to Verified Market Research, Asia Pacific is fastest growing region in global oncology based in vivo (CRO) market.

The Asia-Pacific region is the fastest-growing market for oncology-based in vivo contract research organizations (CROs), driven by rising cancer rates and expanding healthcare infrastructure.

Rapid economic growth, increasing investment in medical research and advances in imaging and diagnostic technology are driving this expansion. Furthermore, improved regulatory conditions and an increasing emphasis on personalized treatment contribute to the region's expansion.

As more pharmaceutical and biotech businesses seek cost-effective and novel research solutions, Asia-Pacific is emerging as a key hub for oncology-based in vivo investigations, providing considerable growth and development prospects in the CRO sector.

Global Oncology Based In Vivo (CRO) Market: Segmentation Analysis

The Global Oncology Based In Vivo (CRO) Market is segmented based on Indication, Model and Geography.

Global Oncology Based In Vivo (CRO) Market, By Indication

• Blood Cancer
• Solid Tumors

Based on Indication, the Global Oncology Based In Vivo (CRO) Market is separated into Blood Cancer and Solid Tumors. Solid tumors dominate the worldwide oncology-based in vivo CRO market due to their higher occurrence and the considerable research needed for targeted medications and individualized treatments. While blood cancers are substantial, they represent a lower fraction of market activity when contrasted to the broader and more diverse research focus on solid tumors.

Global Oncology Based In Vivo (CRO) Market, By Model

• Syngeneic Model
• Xenograft

Based on Model, Global Oncology Based In Vivo (CRO) Market is divided into Syngeneic Model and Xenograft. The xenograft model presently dominates the worldwide oncology-based in vivo CRO market due to its superior capacity to imitate human tumor microenvironments. This paradigm is preferred for assessing therapeutic efficacy and mechanisms in cancer research, as it provides useful information for designing targeted therapies and individualized treatments.

Global Oncology Based In Vivo (CRO) Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on the Geography, the Global Oncology Based In Vivo (CRO) Market divided into North America, Europe, Asia Pacific and Rest of the World. North America leads the worldwide oncology-based in vivo CRO market due to its advanced research infrastructure, significant expenditure in cancer research and established healthcare systems. This region leads in market share and innovation, although the Asia-Pacific area is rapidly expanding and gaining prominence.

Key Players

• The Global Oncology Based In Vivo (CRO) Market study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• Charles River Laboratory, ICON Plc, Thermo Fisher Scientific, Inc., Eurofins Scientific, Taconic Biosciences, Crown Bioscience, LabCorp, WuXi AppTec, EVOTEC, The Jackson Laboratory.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share and market ranking analysis of the above-mentioned players globally.

• Global Oncology Based In Vivo (CRO) Market Recent Developments
• In November 2023, Crown Bioscience introduced the OrganoidXploreTM service. Our organoid panel screening tool provides rapid, reliable and clinically relevant results, accelerating preclinical research. Oncology drug discovery is changing the landscape of cancer treatment development.
• In October 2023, Coeptis Therapeutics Holdings, Inc. disclosed research on the potential of the SNAP-CAR T-cell platform to target multiple antigens. The study used SNAP-CAR technology to show its adaptive antigen-targeting capabilities in human tumor xenograft models, both in vivo and in vitro.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Oncology Based In-Vivo CRO Market, By Service Type

• Pharmacokinetic Studies
• Toxicology Testing
• Efficacy Studies
• Bioanalysis and Analytical Services

5. Oncology Based In-Vivo CRO Market, By Indication

• Solid Tumors
• Hematological Malignancies
• Others

6. Oncology Based In-Vivo CRO Market, By End User

• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations (CROs)
• Academic and Research Institutes
• Others

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Charles River Laboratories International Inc.
• Envigo CRS
• Eurofins Scientific SE
• Icon plc
• Labcorp Co. Holdings
• Medpace Holdings Inc.
• PAREXEL International Corporation
• Pharmaceutical Product Development LLC (PPD)
• Syneos Health Inc.
• WuXi AppTec Co., Ltd.

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References